In 1980, while working as a pediatric resident in the newborn intensive care unit of a University-affiliated hospital, I was called urgently to the delivery room. The attending obstetrician had delivered a full-term infant without complications just minutes before my arrival.

Transition from parenteral prostanoids to oral selexipag may be considered in select patients with pulmonary arterial hypertension (PAH) to reduce the therapeutic burden imposed on patients and caregivers, but its safety and efficacy remain uncertain.

Pulmonary hypertension (PH) significantly impacts outcomes in heart failure with preserved ejection fraction (HFpEF), especially with right ventricular dysfunction (RVD), yet effective treatments are limited. This study retrospectively evaluated sacubitril-valsartan's effects on pulmonary pressures, RV function, and clinical outcomes in 20 severe HFpEF-PH patients. 

Pulmonary arterial hypertension (PAH) is a pulmonary disease associated with alterations in gut microbiota. We aimed to identify potential diagnostic genes causally associated with gut microbiota and PAH.

In the recent paper, Pulmonary Vascular Compromise is Associated with Survival in Pediatric Pulmonary Hypertension: a New Computational Model by Niccum et al. [1] presents an innovative computational model reframing pulmonary vascular disease through the concept of pulmonary vascular compromise (PVC), a quantifiable estimate of the proportion of pulmonary vascular surface area lost relative to an idealized normal pulmonary vascular capacity.

Pulmonary arterial hypertension (PAH) is a life-threatening condition with no cure, making research into its underlying mechanisms critical. The platelet-derived growth factor (PDGF) signaling pathway plays a crucial role in vascular remodeling, a key factor in PAH progression. 

Pulmonary Arterial Hypertension (PAH) is a rare, chronic and progressive disease affecting the heart and lungs. Endothelin receptor antagonist (ERA) + phosphodiesterase type 5 inhibitor (PDE5i) treatment is recommended for all PAH patients. 

Pulmonary artery wedge pressure is a crucial measurement for differentiating between hemodynamic categories of pulmonary hypertension (PH), particularly Groups 1 and 2. In this prospective study, we analyzed the diagnostic utility of checking wedge oxygen saturation to confirm wedge position during right heart catheterization in patients referred for PH.

'Microbes/Parasites and Sex Differences in PVDs' is part of the Virtual Symposium Series by the iPVD, a global education programme that highlights top-notch research on inflammation and infectious PVD.

Pericardial effusion (PEF) in PAH may be a marker of worsening disease or associated with autoimmune conditions. Sotatercept was not initially reported as associated with the development or progression of PEF. We describe PAH patients taking sotatercept who were found to have new or worsening PEF and examine associated comorbidities.